Management of a New Isolated Metastasis during Sunitinib Treatment in Renal Cell Carcinoma Patients: A Lesson from Two Cases.
AffiliationDepartment of Medical Oncology, Christie NHS Foundation Trust, Manchester, UK.
MetadataShow full item record
AbstractMetastatic renal cell carcinoma (mRCC) is a difficult to treat malignancy and currently Sunitinib is a standard of care first-line therapy. A new metastasis during the treatment is considered a sign of drug failure and alternative therapeutic methods should be tried. Here, we report 2 cases of newly diagnosed isolated metastasis during Sunitinib treatment of mRCC patients. Our management plan included local palliative therapy to the lesion followed by recommencing of Sunitinib. This resulted in a good symptomatic relief locally as well as good overall control of the disease.
CitationManagement of a New Isolated Metastasis during Sunitinib Treatment in Renal Cell Carcinoma Patients: A Lesson from Two Cases. 2010: Urol Int